FY2024 EPS Estimates for Danaher Cut by Leerink Partnrs

Danaher Co. (NYSE:DHR) – Leerink Partnrs reduced their FY2024 earnings per share estimates for Danaher in a note issued to investors on Tuesday, October 22nd. Leerink Partnrs analyst P. Souda now anticipates that the conglomerate will post earnings per share of $7.49 for the year, down from their prior estimate of $7.60. The consensus estimate for Danaher’s current full-year earnings is $7.59 per share. Leerink Partnrs also issued estimates for Danaher’s Q1 2025 earnings at $2.06 EPS, Q2 2025 earnings at $1.90 EPS, Q3 2025 earnings at $1.87 EPS, Q4 2025 earnings at $2.47 EPS, FY2025 earnings at $8.30 EPS and FY2026 earnings at $9.31 EPS.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the firm earned $2.02 earnings per share. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year.

Other analysts have also issued reports about the stock. The Goldman Sachs Group increased their target price on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Raymond James dropped their target price on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Wednesday. Robert W. Baird dropped their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday. Stephens reiterated an “overweight” rating and set a $315.00 target price on shares of Danaher in a report on Wednesday. Finally, Wells Fargo & Company started coverage on shares of Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 target price for the company. Seven research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $287.28.

Danaher Stock Performance

Danaher stock opened at $245.41 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The firm has a 50-day moving average of $270.00 and a 200-day moving average of $260.34. The firm has a market cap of $181.77 billion, a P/E ratio of 41.59, a P/E/G ratio of 4.49 and a beta of 0.83. Danaher has a 1-year low of $182.09 and a 1-year high of $281.70.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a dividend of $0.27 per share. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s payout ratio is 18.31%.

Insider Activity

In other news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,059 shares of company stock worth $8,400,897. Insiders own 11.10% of the company’s stock.

Institutional Investors Weigh In On Danaher

Large investors have recently added to or reduced their stakes in the stock. Tsfg LLC grew its position in Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares during the period. CarsonAllaria Wealth Management Ltd. bought a new stake in Danaher in the 2nd quarter worth approximately $25,000. nVerses Capital LLC bought a new stake in Danaher in the 2nd quarter worth approximately $25,000. Redmont Wealth Advisors LLC bought a new stake in Danaher in the 1st quarter worth approximately $30,000. Finally, MFA Wealth Advisors LLC bought a new stake in shares of Danaher during the 2nd quarter valued at $51,000. Institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.